E. Anders Kolb

11.8k citations

283 papers · 6.2k · h-index 46

Impact in

Hematology top 0.5%
- Acute Myeloid Leukemia Research
Oncology top 1%
- CAR-T cell therapy research

Papers in

Molecular Biology 149
- Protein Degradation and Inhibitors 30
- Cancer therapeutics and mechanisms 29
Hematology 121
- Acute Myeloid Leukemia Research 100
- Multiple Myeloma Research and Treatments 21

Co-authors: Richard Görlick (100 shared papers)Peter J. Houghton (84 shared papers)Malcolm A. Smith (93 shared papers)John M. Maris (77 shared papers)Stephen T. Keir (67 shared papers)C. Patrick Reynolds (68 shared papers)Richard B. Lock (62 shared papers)Christopher L. Morton (47 shared papers)
Journals: Pediatric Blood & Cancer (86 papers)Blood (63 papers)Journal of Clinical Oncology (14 papers)Cancer Research (13 papers)Molecular Cancer Therapeutics (11 papers)
Partner nations: United States Australia Canada

In The Last Decade

E. Anders Kolb

270 papers receiving 6.2k citations

Peers

Countries citing papers authored by E. Anders Kolb

Since Specialization

Citations

This map shows the geographic impact of E. Anders Kolb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Anders Kolb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Anders Kolb more than expected).

Fields of papers citing papers by E. Anders Kolb

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Anders Kolb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Anders Kolb. The network helps show where E. Anders Kolb may publish in the future.

Co-authors

The 25 scholars most cited alongside E. Anders Kolb, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with E. Anders Kolb Line = papers co-authored together E. Anders Kolb links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 283 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Dickkopf 3 Inhibits Invasion and Motility of Saos-2 Osteosarcoma Cells by Modulating the Wnt-β-Catenin Pathway Cancer Research ·Bang H. Hoang, Tadahiko Kubo, John H. Healey, Rui Yang, Saminathan S. Nathan, E. Anders Kolb, BethAnne Mazza, Paul A. Meyers, Richard Görlick	2004	230
2	Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP) Pediatric Blood & Cancer ·John M. Maris, Christopher L. Morton, Richard Görlick, E. Anders Kolb, Richard B. Lock, Hernán Carol, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, Jianrong Wu, Malcolm A. Smith, Peter J. Houghton	2010	178
3	Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by the pediatric preclinical testing program Pediatric Blood & Cancer ·E. Anders Kolb, Richard Görlick, Peter J. Houghton, Christopher L. Morton, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, John M. Maris, Stephen T. Keir, Catherine A. Billups, Malcolm A. Smith	2008	136
4	MicroRNAs and Potential Targets in Osteosarcoma: Review Frontiers in Pediatrics ·Valerie B. Sampson, Soonmoon Yoo, Asmita Kumar, Nancy S. Vetter, E. Anders Kolb	2015	134
5	Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing’s Family of Tumors in Children and Young Adults Journal of Clinical Oncology ·E. Anders Kolb, Brian H. Kushner, Richard Görlick, Caroline Laverdière, John H. Healey, Michael P. LaQuaglia, Andrew G. Huvos, Jing Qin, Ha Thanh Vu, Leonard H. Wexler, Suzanne L. Wolden, Paul A. Meyers	2003	128
6	Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program Pediatric Blood & Cancer ·Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard Görlick, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, John M. Maris, Stephen T. Keir, Catherine A. Billups, Malcolm A. Smith	2007	125
7	Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy Cancer Research ·Christopher C. Mills, E. Anders Kolb, Valerie B. Sampson	2018	115
8	Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program Pediatric Blood & Cancer ·Richard B. Lock, Hernán Carol, Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard Görlick, C. Patrick Reynolds, John M. Maris, Stephen T. Keir, Jianrong Wu, Malcolm A. Smith	2007	99
9	Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program Pediatric Blood & Cancer ·Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, Nino Keshelava, John M. Maris, Stephen T. Keir, Jianrong Wu, Malcolm A. Smith	2007	98
10	Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program Pediatric Blood & Cancer ·John M. Maris, Joshua Courtright, Peter J. Houghton, Christopher L. Morton, Richard Görlick, E. Anders Kolb, Richard B. Lock, Mayamin Tajbakhsh, C. Patrick Reynolds, Stephen T. Keir, Jianrong Wu, Malcolm A. Smith	2007	97
11	Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program Clinical Cancer Research ·Malcolm A. Smith, C. Patrick Reynolds, Min H. Kang, E. Anders Kolb, Richard Görlick, Hernán Carol, Richard B. Lock, Stephen T. Keir, John M. Maris, Catherine A. Billups, Dmitry Lyalin, Raushan T. Kurmasheva, Peter J. Houghton	2014	90
12	Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group Haematologica ·Richard Aplenc, Soheil Meshinchi, Lillian Sung, Todd A. Alonzo, John Choi, Brian T. Fisher, Robert B. Gerbing, Betsy Hirsch, Terzah M. Horton, Samir B. Kahwash, John E. Levine, Michael R. Loken, Lisa Eidenschink Brodersen, Jessica A. Pollard, Susana C. Raimondi, E. Anders Kolb, Alan S. Gamis	2020	90
13	Delivery of care consistent with the psychosocial standards in pediatric cancer: Current practices in the United States Pediatric Blood & Cancer ·Michele A. Scialla, Kimberly S. Canter, Fang Fang Chen, E. Anders Kolb, Eric Sandler, Lori Wiener, Anne E. Kazak	2017	85
14	Initial testing of a monoclonal antibody (IMC‐A12) against IGF‐1R by the pediatric preclinical testing program Pediatric Blood & Cancer ·Peter J. Houghton, Christopher L. Morton, Richard Görlick, E. Anders Kolb, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, John M. Maris, Jianrong Wu, Malcolm A. Smith	2010	83
15	The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML Blood ·Emily Heikamp, Jill A. Henrich, Florian Perner, Eric Wong, Charlie Hatton, Yanhe Wen, Sonali P. Barwe, Anilkumar Gopalakrishnapillai, Haiming Xu, Hannah J. Uckelmann, Sumiko Takao, Yaniv Kazansky, Yana Pikman, Gerard M. McGeehan, E. Anders Kolb, Alex Kentsis, Scott A. Armstrong	2021	82
16	Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program Molecular Cancer Therapeutics ·Peter J. Houghton, Christopher L. Morton, Richard Görlick, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, Min H. Kang, John M. Maris, Stephen T. Keir, E. Anders Kolb, Jianrong Wu, Amy Wozniak, Catherine A. Billups, Larry Rubinstein, Malcolm A. Smith	2010	79
17	Initial testing (stage 1) of AZD6244 (ARRY‐142886) by the pediatric preclinical testing program Pediatric Blood & Cancer ·E. Anders Kolb, Richard Görlick, Peter J. Houghton, Christopher L. Morton, Geoffrey Neale, Stephen T. Keir, Hernán Carol, Richard B. Lock, Doris A. Phelps, Min H. Kang, C. Patrick Reynolds, John M. Maris, Catherine A. Billups, Malcolm A. Smith	2010	77
18	Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer Cancer Chemotherapy and Pharmacology ·Hernán Carol, Ingrid Boehm, C. Patrick Reynolds, Min H. Kang, John M. Maris, Christopher L. Morton, Richard Görlick, E. Anders Kolb, Stephen T. Keir, Jianrong Wu, A. E. Wozniak, Yu Yang, Mark Manfredi, Jeffrey Ecsedy, Jianmin Wang, Geoffrey Neale, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock	2011	77
19	Parallel Randomized Trials of Risk-Based Therapy for Fetal Alloimmune Thrombocytopenia Obstetrics and Gynecology ·Richard L. Berkowitz, E. Anders Kolb, Janice G. McFarland, Megan Wissert, Andrea Primani, Martin Lesser, James B. Bussel	2006	77
20	Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia Leukemia ·Nicole McNeer, John Philip, Heather Geiger, Rhonda E. Ries, Vincent‐Philippe Lavallée, Michael F. Walsh, Minita Shah, Kanika Arora, Anne‐Katrin Emde, Nicolas Robine, Todd A. Alonzo, E. Anders Kolb, Alan S. Gamis, Malcolm A. Smith, Daniela S. Gerhard, Jaime Guidry-Auvil, Soheil Meshinchi, Alex Kentsis	2019	77

About E. Anders Kolb

E. Anders Kolb is a scholar working on Molecular Biology, Hematology, Oncology, Public Health, Environmental and Occupational Health and Neurology, having authored 283 papers that have together received 6.2k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (100 papers), Neuroblastoma Research and Treatments (41 papers), Acute Lymphoblastic Leukemia research (37 papers), Protein Degradation and Inhibitors (30 papers), Cancer therapeutics and mechanisms (29 papers), Multiple Myeloma Research and Treatments (21 papers), CAR-T cell therapy research (21 papers) and Sarcoma Diagnosis and Treatment (19 papers). The work is most often cited by research in Hematology (1.2k citations), Oncology (1.8k citations), Cancer Research (919 citations), Neurology (857 citations) and Molecular Biology (3.1k citations). E. Anders Kolb has collaborated with scholars based in United States, Australia and Canada. Frequent co-authors include Richard Görlick, Peter J. Houghton, Malcolm A. Smith, John M. Maris, Stephen T. Keir, C. Patrick Reynolds, Richard B. Lock, Christopher L. Morton, Hernán Carol and Min H. Kang. Their work appears in journals such as Pediatric Blood & Cancer, Blood, Journal of Clinical Oncology, Cancer Research and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

E. Anders Kolb

Impact in

Papers in i

In The Last Decade

E. Anders Kolb

Peers

Countries citing papers authored by E. Anders Kolb

Fields of papers citing papers by E. Anders Kolb

All Works

About E. Anders Kolb

Explore authors with similar magnitude of impact

Papers in